stockrowRallybio Corporation
RLYBRallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
Follow RLYB
Alert me
Rallybio Corporation (RLYB) Return on invested capital
Rallybio Corporation's return on invested capital over the twelve months to 30 September 2026 was −944.4%, down 302.6 percentage points from fiscal 2025 (−641.8%). Over the past ten years it has ranged from −13,135.5% (fiscal 2022) to 0.00% (fiscal 2024); the current reading is higher than 43% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −641.8% | (641.77) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 13,135.45 |
| FY2022 | −13,135.5% | (2,489.93) |
| FY2021 | −10,645.5% | (10,645.52) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| GNLX Genelux Corporation compare | 0.00% |
| CBUS Cibus, Inc. compare | 0.00% |
| MIST Milestone Pharmaceuticals Inc. compare | 0.00% |
| VTVT vTv Therapeutics Inc. compare | 0.00% |
| PLYX Polaryx Therapeutics, Inc. compare | 0.00% |
| EQ Equillium, Inc. compare | 0.00% |
| KZIA Novogen Limited compare | 0.00% |
| ATRA Atara Biotherapeutics, Inc. compare | 0.00% |
| RLYB Rallybio Corporation | −944.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)